A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy

Giovanna Scarfone, Antonella Villa, Fabio Parazzini, Cesarina Sciatta, Giampiero Polverino, Giorgio Bolis

Research output: Contribution to journalArticle

Abstract

Aims and background: To evaluate the toxicity of high-dose ifosfamide in ovarian cancer patients refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Methods: This was an open, non-randomized phase I-II trial of high-dose ifosfamide. Eligibility criteria were: patients aged 18-75 years affected by ovarian cancer with refractory or resistant disease or early relapse after first-line treatment including platinum or paclitaxel. Three patients were given escalating ifosfamide doses; if no severe adverse events occurred, the ifosfamide dose was increased. The starting dose of ifosfamide was 10 g/m 2 iv and the dose increase was 1 g/m 2 every four weeks for a total of five courses; 12 g/m 2 was the maximum ifosfamide dose to be administered. The trial then progressed to a phase II trial, in which ifosfamide was given at the maximum tolerated dose reached during the escalating dose phase. Results: A total of 36 patients entered the trial. Nine patients were involved in phase I of the study; 3 received 10 g/m 2 ifosfamide, 3 11 g/m 2 and 3 12 g/m 2. Of the 32 evaluable patients 6 (18.8%) achieved a complete response and three (9.4%) a partial response, giving an overall response rate of 28.1% (95% CI, 15-61% based on Poisson's approximation). The median number of ifosfamide courses was five. G1, G2 and G3 neurotoxicity was reported in 3 (8%), 2 (5%) and 2 (5%) patients, respectively. Conclusion: This phase I-II trial indicates that high-dose ifosfamide has some activity but also a relevant degree of toxicity in resistant or refractory platinum and paclitaxel-pretreated ovarian cancer.

Original languageEnglish
Pages (from-to)217-219
Number of pages3
JournalTumori
Volume85
Issue number4
Publication statusPublished - Jul 1999

Fingerprint

Ifosfamide
Paclitaxel
Platinum
Ovarian Neoplasms
Drug Therapy
Maximum Tolerated Dose
Recurrence

Keywords

  • Chemotherapy
  • Ifosfamide
  • Ovarian cancer
  • Recurrence

ASJC Scopus subject areas

  • Cancer Research

Cite this

A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. / Scarfone, Giovanna; Villa, Antonella; Parazzini, Fabio; Sciatta, Cesarina; Polverino, Giampiero; Bolis, Giorgio.

In: Tumori, Vol. 85, No. 4, 07.1999, p. 217-219.

Research output: Contribution to journalArticle

@article{2b8b2dfee6e944039d13b85b27c202de,
title = "A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy",
abstract = "Aims and background: To evaluate the toxicity of high-dose ifosfamide in ovarian cancer patients refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Methods: This was an open, non-randomized phase I-II trial of high-dose ifosfamide. Eligibility criteria were: patients aged 18-75 years affected by ovarian cancer with refractory or resistant disease or early relapse after first-line treatment including platinum or paclitaxel. Three patients were given escalating ifosfamide doses; if no severe adverse events occurred, the ifosfamide dose was increased. The starting dose of ifosfamide was 10 g/m 2 iv and the dose increase was 1 g/m 2 every four weeks for a total of five courses; 12 g/m 2 was the maximum ifosfamide dose to be administered. The trial then progressed to a phase II trial, in which ifosfamide was given at the maximum tolerated dose reached during the escalating dose phase. Results: A total of 36 patients entered the trial. Nine patients were involved in phase I of the study; 3 received 10 g/m 2 ifosfamide, 3 11 g/m 2 and 3 12 g/m 2. Of the 32 evaluable patients 6 (18.8{\%}) achieved a complete response and three (9.4{\%}) a partial response, giving an overall response rate of 28.1{\%} (95{\%} CI, 15-61{\%} based on Poisson's approximation). The median number of ifosfamide courses was five. G1, G2 and G3 neurotoxicity was reported in 3 (8{\%}), 2 (5{\%}) and 2 (5{\%}) patients, respectively. Conclusion: This phase I-II trial indicates that high-dose ifosfamide has some activity but also a relevant degree of toxicity in resistant or refractory platinum and paclitaxel-pretreated ovarian cancer.",
keywords = "Chemotherapy, Ifosfamide, Ovarian cancer, Recurrence",
author = "Giovanna Scarfone and Antonella Villa and Fabio Parazzini and Cesarina Sciatta and Giampiero Polverino and Giorgio Bolis",
year = "1999",
month = "7",
language = "English",
volume = "85",
pages = "217--219",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy

AU - Scarfone, Giovanna

AU - Villa, Antonella

AU - Parazzini, Fabio

AU - Sciatta, Cesarina

AU - Polverino, Giampiero

AU - Bolis, Giorgio

PY - 1999/7

Y1 - 1999/7

N2 - Aims and background: To evaluate the toxicity of high-dose ifosfamide in ovarian cancer patients refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Methods: This was an open, non-randomized phase I-II trial of high-dose ifosfamide. Eligibility criteria were: patients aged 18-75 years affected by ovarian cancer with refractory or resistant disease or early relapse after first-line treatment including platinum or paclitaxel. Three patients were given escalating ifosfamide doses; if no severe adverse events occurred, the ifosfamide dose was increased. The starting dose of ifosfamide was 10 g/m 2 iv and the dose increase was 1 g/m 2 every four weeks for a total of five courses; 12 g/m 2 was the maximum ifosfamide dose to be administered. The trial then progressed to a phase II trial, in which ifosfamide was given at the maximum tolerated dose reached during the escalating dose phase. Results: A total of 36 patients entered the trial. Nine patients were involved in phase I of the study; 3 received 10 g/m 2 ifosfamide, 3 11 g/m 2 and 3 12 g/m 2. Of the 32 evaluable patients 6 (18.8%) achieved a complete response and three (9.4%) a partial response, giving an overall response rate of 28.1% (95% CI, 15-61% based on Poisson's approximation). The median number of ifosfamide courses was five. G1, G2 and G3 neurotoxicity was reported in 3 (8%), 2 (5%) and 2 (5%) patients, respectively. Conclusion: This phase I-II trial indicates that high-dose ifosfamide has some activity but also a relevant degree of toxicity in resistant or refractory platinum and paclitaxel-pretreated ovarian cancer.

AB - Aims and background: To evaluate the toxicity of high-dose ifosfamide in ovarian cancer patients refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Methods: This was an open, non-randomized phase I-II trial of high-dose ifosfamide. Eligibility criteria were: patients aged 18-75 years affected by ovarian cancer with refractory or resistant disease or early relapse after first-line treatment including platinum or paclitaxel. Three patients were given escalating ifosfamide doses; if no severe adverse events occurred, the ifosfamide dose was increased. The starting dose of ifosfamide was 10 g/m 2 iv and the dose increase was 1 g/m 2 every four weeks for a total of five courses; 12 g/m 2 was the maximum ifosfamide dose to be administered. The trial then progressed to a phase II trial, in which ifosfamide was given at the maximum tolerated dose reached during the escalating dose phase. Results: A total of 36 patients entered the trial. Nine patients were involved in phase I of the study; 3 received 10 g/m 2 ifosfamide, 3 11 g/m 2 and 3 12 g/m 2. Of the 32 evaluable patients 6 (18.8%) achieved a complete response and three (9.4%) a partial response, giving an overall response rate of 28.1% (95% CI, 15-61% based on Poisson's approximation). The median number of ifosfamide courses was five. G1, G2 and G3 neurotoxicity was reported in 3 (8%), 2 (5%) and 2 (5%) patients, respectively. Conclusion: This phase I-II trial indicates that high-dose ifosfamide has some activity but also a relevant degree of toxicity in resistant or refractory platinum and paclitaxel-pretreated ovarian cancer.

KW - Chemotherapy

KW - Ifosfamide

KW - Ovarian cancer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=0032840444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032840444&partnerID=8YFLogxK

M3 - Article

C2 - 10587020

AN - SCOPUS:0032840444

VL - 85

SP - 217

EP - 219

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -